

314, T. V. Indusstrial Estate, S.K. Ahire Marg, Worli, Mumbai - 400 030. India

> Tel.: + 91 22 6663 5456 Fax: +91 22 6663 5460

E-mail: auro@aurolabs.com Web: www.aurolabs.com

Reg. Off. / Mfg. Unit: K-56, M. I. D. C. Tarapur, Dist. Palghar, Maharashtra - 401506. CIN No. L33125MH1989PLC051910

Date: May 23, 2019.

To
The Deputy General Manager,
BSE Limited
PhirozeJeejeebhoy Towers,
Dalal Street, Fort,
Mumbai - 400001.

Reg: Security Code No. 530233:

Sub: Outcome of Board Meeting held on May 23, 2019.

Dear Sir,

Pursuant to provisions of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 we wish to inform you that the Board of Directors of the Company at its Meeting held today i.e. May 23, 2019 inter-alia, considered following matters:

Financial Results:

Approved the Audited Financial Results of the Company for the quarter and year ended on 31st March, 2019.

Pursuant to provisions of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, we are enclosing herewith the following:

- a) Audited Standalone Financial Results for the quarter and year ended March 31, 2019 along with the Statement of Assets and Liabilities of the Company as on that date.
- Auditors Report on the Financial Results for the quarter and year ended March 31, 2019.
- c) Declaration regarding Auditor's Report with unmodified opinion on the Annual Audited Financial Results of the Company for the financial year ended on March 31, 2019.

MUMBAI

Annual General Meeting:

The Annual General Meeting of the Company will be held on Friday, September 6, 2019.

The meeting of the Board of Directors commenced at 02.30 P. M. and concluded at 03.25 P. M. The results will be published in the newspapers in terms of Regulation 47(1)(b) of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 in due course.

MUMBAI INDIA

Kindly take the above on your record.

Thanking You.

Yours faithfully,

For AURO LABORATORIES LIMITED

SHARAT DEORAH

CHAIRMAN & MANAGING DIRECTOR

(DIN: 00230784)

AURO LABORATORIES LIMITED CIN NO. :- L33125MH1989PLC051910

Regd. Office: K - 56 M.I.D.C INDUSTRIAL AREA, TARAPUR BOISAR, DIST. PALGHAR 401506, MAHARASHTRA

Tel.: +91-22-66635456 Fax:+91-22-66635460 Email. auro@aurolabs.com Web: www.aurolabs.com

ANNEXURE - I

	A	NNEXURE - I				T-110-V
PAR	T-I			W	Rs. I	n Lakhs)
	STATEMENT OF AUDITED FINANCIAL RESULTS FOR THE QUAR	RTER AND YE	AR ENDED 31ST	MARCH 2019		
		3 Months ended	Preceding 3 Months ended	Corresponsing 3 Months ended in the Previous Year	For the yer Ended	Previous Year Ended
Sr.		31.03.2019	31.12.2018	31.03.2018	31.03.2019	31.03.2018
No.	Particulars	(audited)	(Unaudited)	(audited)	(Audited)	(Audited)
1	Income from Operations	200 200 200 200 200 200 200 200 200 200				
	(a) Net Sales/Income from Operations (Net of excise duty)	1,153.02	1227.61	1,127.82	4,682.31	4,079.4
2	Other Income	59.34	7.28	22.65	95.82	51.3
3	Total Revenue (1 + 2)	1,212.36	1,234.89	1,150.47	4,778.13	4,130.7
4	Expenses					0.101.0
tahin e	a. Consumption of raw material	621.14	793.71	660.79	3,013.82	2,461.6
	b. Purchase of Stock-in-trade	23.87	-	1.24	24.91	4.0
	c. (Increase) / decrease in Finished Goods stock	-8.65	(61.63)	(92.49)	(176.59)	6.3
	in trade and work in progress	-				
lly.	d. Employee benefits expense	132.32	96.67	171.92	407.07	369.
	e. Finance Cost	12.57	18.01	5.03	72.22	108.
	f. Depreciation and amortisation expenses	22.42	28.00	20.11	100.92	93.
	g. Other Expenses	177.54	175.61	178.15	728.89	614.
	Total Expenses (4)	981.21	1,050.37	944.75	4,171.24	3,658.
5	Profit / (Loss) before exceptional and extraordinary items and tax (3 ± 4)	231.15	184.52	205.72	606.89	472.
6	Exceptional items			-		-
7	Profit / (Loss) before extraordinary items and tax (5 ± 6)	231.15	184.52	205.72	606.89	472.
8	Extraordinary items	-	-			
9	Profit / (Loss) before tax (7 ± 8)	231.15	184.52	205.72	606.89	472.
10	Tax expense	-	-	-		
	(a) Current tax expesnes for current year	67.76	46.13	-	161.69	127.
	(b) MAT credit (where applicable)	-	-	-		
	(c) Defferered tax	5.25	-	-	5.25	(7.
11	Profit / (Loss) for the period from continuing operation (9± 10)	158.15	138.39	205.72	439.95	352.
12	Profit / (Loss) for discontinuing operations	-		-		
13	Tax expense of discontinuing operations	-	-			
14		158.15	138.39	205.72	439.95	352
15		8.11	(1.34	-	8.11	4
16		166.26	137.05		448.06	357
17		623.25	623.25	623.25	623.25	623
	(Face value of Rs. 10 each)				100000000000000000000000000000000000000	
17				(4)	603.14	251
	per balance sheet of previous accounting year)					
18	Earnings per share (EPS) (Face Value - Rs. 10 per Equity			at 195 17 18 7%		
	(a) Basic	2.54	2.22		7.06	
	(b) Diluted	2.54	2.22	3.30	7.06	5.

MUMBAI · INDIA **Auro Laboratories Limited**

Particulars	As at 31/03/2019	(Rs. In Lak As at 31/03/2018
Alassets	Audited	Audited
ASSETS		
1. Non-Current Assets		
(a) Property, Plant and Equipment	1,458.62	1,302.3
(b) Capital Work -in-Progress	11.60	107.2
(c) Investment Property	100	2
(d) Financial Assets	-	
(i) Investments	4.88	4.8
(ii) Loans	-	313
(iii) Others		5-1
(e) Other non-current assets - Capital Advance	- 22	62
(e) Other Horr-current assets - Capital Advance		
2. Current assets		
(a) Inventories	337.38	149.
(b) Financial Assets		13
(i) Investments	923	35
(ii) Trade Reveivables	850.38	837.
(iii) Cash and cash equivalents	335.88	179.
(iv) Bank balances other than (iii) above	74.88	45.
(v) Loans	-	1
	6125335	
(vi) Others	272 92	414
(vi) Others	272.92	414.2
(vi) Others (c) Other Current Assets TOTAL ASSETS	272.92 - 3346.54	3040.
(c) Other Current Assets	76.552 44.50	1.6
(c) Other Current Assets TOTAL ASSETS EQUITY AND LIABILITIES	76.552 44.50	
(c) Other Current Assets TOTAL ASSETS EQUITY AND LIABILITIES 1. Equity	3346.54	3040
(c) Other Current Assets TOTAL ASSETS EQUITY AND LIABILITIES 1. Equity (a) Equity Share Capital	3346.54 623.25	3040 .
(c) Other Current Assets TOTAL ASSETS EQUITY AND LIABILITIES 1. Equity	3346.54	3040 .
(c) Other Current Assets TOTAL ASSETS EQUITY AND LIABILITIES 1. Equity (a) Equity Share Capital (b) Other Equity	3346.54 623.25	3040 .
(c) Other Current Assets TOTAL ASSETS EQUITY AND LIABILITIES 1. Equity (a) Equity Share Capital (b) Other Equity 2. Liabilities	3346.54 623.25	3040 .
(c) Other Current Assets TOTAL ASSETS EQUITY AND LIABILITIES 1. Equity (a) Equity Share Capital (b) Other Equity 2. Liabilities (l) Non-Current Liabilities	623.25 1,117.95	623.3 674.5
(c) Other Current Assets TOTAL ASSETS EQUITY AND LIABILITIES 1. Equity (a) Equity Share Capital (b) Other Equity 2. Liabilities (l) Non-Current Liabilities (a) Financial Liabilities	623.25 1,117.95	623.3 674.5
(c) Other Current Assets TOTAL ASSETS EQUITY AND LIABILITIES 1. Equity (a) Equity Share Capital (b) Other Equity 2. Liabilities (l) Non-Current Liabilities (a) Financial Liabilities (i) Other Financial Liabilities	623.25 1,117.95	623.2 674.5
(c) Other Current Assets TOTAL ASSETS EQUITY AND LIABILITIES 1. Equity (a) Equity Share Capital (b) Other Equity 2. Liabilities (i) Non-Current Liabilities (a) Financial Liabilities (i) Other Financial Liabilities (b) Provisions	623.25 1,117.95 614.93 194.50	623.2 674.5 617.1 302.0
(c) Other Current Assets TOTAL ASSETS EQUITY AND LIABILITIES 1. Equity (a) Equity Share Capital (b) Other Equity 2. Liabilities (i) Non-Current Liabilities (a) Financial Liabilities (ii) Other Financial Liabilities	623.25 1,117.95	623.2 674.5 617.8 302.0
(c) Other Current Assets TOTAL ASSETS EQUITY AND LIABILITIES 1. Equity (a) Equity Share Capital (b) Other Equity 2. Liabilities (l) Non-Current Liabilities (a) Financial Liabilities (i) Other Financial Liabilities (b) Provisions (c) Deferred Tax Liabilities (Net)	623.25 1,117.95 614.93 194.50	1.6
(c) Other Current Assets TOTAL ASSETS EQUITY AND LIABILITIES 1. Equity (a) Equity Share Capital (b) Other Equity 2. Liabilities (l) Non-Current Liabilities (a) Financial Liabilities (i) Other Financial Liabilities (b) Provisions (c) Deferred Tax Liabilities (Net) (II) Current Liabilities	623.25 1,117.95 614.93 194.50	623.2 674.5 617.1 302.0
(c) Other Current Assets TOTAL ASSETS EQUITY AND LIABILITIES 1. Equity (a) Equity Share Capital (b) Other Equity 2. Liabilities (l) Non-Current Liabilities (a) Financial Liabilities (i) Other Financial Liabilities (b) Provisions (c) Deferred Tax Liabilities (Net) (II) Current Liabilities (a) Financial Liabilities (a) Financial Liabilities	623.25 1,117.95 614.93 194.50 149.67	623.2 674.5 617.6 302.0
(c) Other Current Assets TOTAL ASSETS EQUITY AND LIABILITIES 1. Equity (a) Equity Share Capital (b) Other Equity 2. Liabilities (l) Non-Current Liabilities (a) Financial Liabilities (b) Provisions (c) Deferred Tax Liabilities (Net) (II) Current Liabilities (a) Financial Liabilities (b) Frovisions (c) Deferred Tax Liabilities (d) Financial Liabilities (e) Financial Liabilities (f) Trade Payables	623.25 1,117.95 614.93 194.50 149.67	623.2 674.5 617.8 302.0
(c) Other Current Assets TOTAL ASSETS EQUITY AND LIABILITIES 1. Equity (a) Equity Share Capital (b) Other Equity 2. Liabilities (l) Non-Current Liabilities (a) Financial Liabilities (i) Other Financial Liabilities (b) Provisions (c) Deferred Tax Liabilities (Net) (II) Current Liabilities (a) Financial Liabilities (b) Current Liabilities (c) Trade Payables (d) Other Current Liabilities	623.25 1,117.95 614.93 194.50 149.67 518.32 78.10	623.2 674.5 617.6 302.0 144.6
(c) Other Current Assets TOTAL ASSETS EQUITY AND LIABILITIES 1. Equity (a) Equity Share Capital (b) Other Equity 2. Liabilities (l) Non-Current Liabilities (a) Financial Liabilities (b) Provisions (c) Deferred Tax Liabilities (Net) (II) Current Liabilities (a) Financial Liabilities (b) Frovisions (c) Deferred Tax Liabilities (d) Financial Liabilities (e) Financial Liabilities (f) Trade Payables	623.25 1,117.95 614.93 194.50 149.67	623.3 674.5 617.3 302.0



Notes:

- The above audtied financial results for the qarter and year ended 31st March, 2019 were reviewed by the Audit Committee and thereafter approved by the Board of Directors at meeting held on 23rd May, 2019.
- The Company operates in single segment i.e. "Pharmaceuticals", and hence does not have any additional disclosures to be made under Ind As 108 on operating Segments.
- 3) The above audited results, published in accordance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, have been prepared in accordance with Indian Accounting Standards (IND AS) notified under section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standard) Rules, 2015; Companies (Indian Accounting Standards) (Amendment) Rules, 2016 and guidelines issued by the Securities and Exchange Board of India (SEBI) and other accounting principles generally accepted in India.
- 4) Figures of last Quarter are the balanceing figures between audited figures in respect of the full financial year and the publised year to the date upto the third quarter of the current financial year.
- 5) Figures for the Previous period have been regrouped/reclassified whereever necessary to conform to current period's classifications.

FOR AND ON BEHALF OF THE BOARD OF DIRECTORS AURO LABORATORIES LIMITED

RATOR

MUMBAI

INDIA

SHARAT DEORAH MANAGING DIRECTOR DIN NO. 00230784

Place : Mumbai Date : 23.05.2019



314, T. V. Indusstrial Estate, S.K. Ahire Marg, Worli, Mumbai - 400 030. India

> Tel.: + 91 22 6663 5456 Fax: +91 22 6663 5460

E-mail: auro@aurolabs.com Web: www.aurolabs.com

Reg. Off. / Mfg. Unit: K-56, M. I. D. C. Tarapur, Dist. Palghar, Maharashtra - 401506. CIN No. L33125MH1989PLC051910

Date: May 23, 2019.

To

BSE Limited,

Corporate Relationship Department,
Phiroze Jeejeebhoy Towers,
Dalal Street,

Mumbai - 400 001

Reg: Security Code No. 530233

Sub: <u>Declaration pursuant to Regulation 33(3) (d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.</u>

Pursuant to the provision of Regulation 33 (3) (d) of SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015 as amended by SEBI Notification No. SEBI/LAD-NRO/GN/2016-17/001 dated May 25, 2016 and SEBI Circular No. CIR/CFD/CMD/56/2016 dated May 27, 2016, we hereby confirm that the Audit Reports by M/s. Khurdia Jain & Co, Chartered Accountants, Mumbai on the Audited Financial Results of the Company for the quarter and year ended March 31, 2019 is with Unmodified Opinion.

Kindly take the same on your record.

Thanking you,

FOR AURO LABORATORIES LIMITED

SHARAT DEORAH CHAIRMAN & MANAGING DIRECTOR

[DIN: 00230784]



To,
The Board of Directors,
Auro Laboratories Limited.

- We have audited the accompanying Statement of Standalone Financial Results of Auro Laboratories Ltd. ("the company") for the quarter and year ended March 31, 2019, attached herewith, being submitted by the company pursuant to the requirement of regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. "CIR/CFD/FAC/62/2016" dated July 05, 2016 and "CIR/IMD/DF1/69/2016" dated August 10, 2016.
- 2. This Statement is the responsibility of the Company's Management and is approved by the Board of Directors. The Statement as it relates to the quarter ended March 31, 2019, has been compiled from the related interim condensed standalone financial statements prepared in accordance with Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34") and as it relates to the year ended March 31, 2019, had been compiled from the related annual standalone financial statements prepared under Section 133 of the Companies Act, 2013 read with rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express an opinion on the Statement based on our audit of such interim condensed standalone financial statements and annual standalone financial statements.

Further, we report that the figures for the quarter ended March 31, 2019 represent the derived figures between the audited figures in respect of the financial year ended March 31, 2019 and the published year to date figures up to December 31, 2018 being the date of the end of the third quarter of the current financial year, which were subjected to a limited review as stated above as required under the Listing Regulations and circular.

 We conducted our audit in accordance with the Standards on Auditing issued by Institute of Chartered Accountants of India. Those standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the statement is free from material misstatement(s).





An audit involves performing procedures to obtain audit evidence about the amounts and the disclosures in the statement. The procedures selected depend on auditor's judgment, including the assessment of the risks of material misstatement of the Statement, whether due to fraud or error. In making those risk assessments, the auditor considers internal financial controls relevant to the Company's preparation and fair presentation of the Statement in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal financial control. An audit also includes evaluating the appropriateness of the accounting policies used and reasonableness of the accounting estimates made by the Management, as well as evaluating the overall presentation of the statements.

We believe that the evidence obtained by us, is sufficient appropriate to provide a basis for our audit opinion.

- 4. In our opinion and the best of our information and according to the explanations given to us, the Statement:
 - (i) is presented in accordance with requirements of Regulations 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, as modified by Circular No. "CIR/CFD/FAC/62/2016" dated July 05, 2016 and "CIR/IMD/DF1/69/2016" dated August 10, 2016, and
 - (ii) give a true and fair view, in conformity with aforesaid Indian Accounting Standards and other accounting principles generally accepted in India, of the profit, total comprehensive income and other financial information of the Company for the quarter and year ended March 31, 2019.

DIA JAIN

For Khurdia Jain & Co.

Chartered Accountants (Firm Reg. No. 120263W)

10 -1/20

Sampat Khurdia

Partner

Membership No. 033615

Place: Mumbai Date: 23/05/2019